Voyager Therapeutics Inc (NASDAQ:VYGR) released its earnings report for 4Q2015, reporting a net loss of $0.67 per share. Analysts had expected the company to report a loss of $0.5 per share. The company’s revenue for the period stood at $4.9 million. However, for its FY2015 results, Voyager was able to post a net profit of $9.14 per share, with revenue of $17.3 million.

Updating investors on the events of the FY2015, VYGR CEO, Steve Paul, stated that it was a momentous year for the company. He particularly pointed out the collaboration with Sanofi Genzyme. The CEO also highlighted the company’s series B financing and a successful IPO, conducted during the year.

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) has been reporting a weak growth in sales, which began last quarter. The stock was recently reviewed by analysts at TheStreet, on March 10. The analysts updated their scores for the company, awarding it an average rating of hold, with a C- score.

The score is based on the company’s strong financial position and even though the company has some debt, it is well within reasonable levels. Furthermore, Enzon also has expanding profit margins, which further strengthen its position. However, the company’s weakness mainly lies in the decline of its net income and a weak operating cash flow. Furthermore, the stock has exhibited a disappointing performance itself.

Hemispherx BioPharma, Inc (NYSEMKT:HEB) is expected to report its 4Q2015 earnings today. The stock has been underperforming the S&P500 by 11.6%, since it began its decline in August 2015. Analysts have awarded an average rating of buy to the stock, with a target price of $0.96, in the next 12-months. This is despite a rise in institutional sentiment of the stock. A total of 3 institutional investors are known to have sold the stock, with another 2 reducing their position in the company. Furthermore, the company is yet to report positive earnings, despite having two products in the market. The current market cap of HEB is $39.5 million.